Synchron Raises $200 Million in Series D Funding
New York-based Synchron, a brain-computer interface (BCI) company, secured $200 million in Series D funding, raising its total capital to $345 million. The fundraising round was led by Double Point Ventures, with ongoing support from ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
New Investors and Funding Purpose
New participants include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. Synchron plans to use the investment to expand its operations in New York and San Diego and to speed up its clinical trials and BCI commercialization.
About Synchron’s Stentrode BCI
The company's key product, the Stentrode, is a non-surgical endovascular brain-computer interface designed to enhance mobility, communication, and independence for people with paralysis. The device is implanted via a catheter procedure into the brain and interacts with the motor cortex through blood vessels.
- It converts brain activity into digital commands.
- Allows hands-free control of digital devices.
- Has been implanted in 10 paralysis patients across Australian and U.S. clinical trials.
Operational Expansion Plans
Synchron intends to grow its New York office, where its cognitive AI division develops models based on brain data, and its engineering hub in San Diego.
"Synchron's Stentrode BCI is a non-surgical endovascular brain-computer interface platform designed to help improve mobility, communication and independence for individuals with paralysis."
Summary: Synchron’s substantial funding round aims to advance its innovative brain-computer interface technology, accelerate clinical trials, and expand key operations in New York and San Diego.